Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 20:14:1759720X221090297.
doi: 10.1177/1759720X221090297. eCollection 2022.

Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)

Win Min Oo  1 , David J Hunter  2
Affiliations
Review

Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)

Win Min Oo et al. Ther Adv Musculoskelet Dis. .

Abstract

In spite of a major public health burden with increasing prevalence, current osteoarthritis (OA) management is largely palliative with an unmet need for effective treatment. Both industry and academic researchers have invested a vast amount of time and financial expense to discover the first diseasing-modifying osteoarthritis drugs (DMOADs), with no regulatory success so far. In this narrative review, we discuss repurposed drugs as well as investigational agents which have progressed into phase II and III clinical trials based on three principal endotypes: bone-driven, synovitis-driven and cartilage-driven. Then, we will briefly describe the recent failures and lessons learned, promising findings from predefined post hoc analyses and insights gained, novel methodologies to enhance future success and steps underway to overcome regulatory hurdles.

Keywords: DMOADs; disease-modifying drugs; endotype; intra-articular therapy; osteoarthritis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: D.J.H. provides consulting advice on scientific advisory boards for Pfizer, Lilly, TLCBio, Novartis, Tissuegene and Biobone. W.M.O. has no conflict of interest.

Figures

Figure 1.
Figure 1.
The three endotypes of OA: (1) bone-driven endotype, (2) synovitis-driven endotype and (3) cartilage-driven endotype.
Figure 2.
Figure 2.
Repurposed or invesigational drugs related to the three main OA endotypes (phase II and III RCTs).
See this image and copyright information in PMC

References

    1. Oo WM, Yu SP, Daniel MS, et al.. Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics. Expert Opin Emerg Drugs 2018; 23: 331–347. - PubMed
    1. Cui A, Li H, Wang D, et al.. Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. EClinicalMedicine 2020; 29–30: 100587. - PMC - PubMed
    1. Lo J, Chan L, Flynn S. A systematic review of the incidence, prevalence, costs, and activity and work limitations of amputation, osteoarthritis, rheumatoid arthritis, back pain, multiple sclerosis, spinal cord injury, stroke, and traumatic brain injury in the United States: a 2019 update. Arch Phys Med Rehabil 2021; 102: 115–131. - PMC - PubMed
    1. Leifer VP, Katz JN, Losina E. The burden of OA-health services and economics. Osteoarthritis Cartilage 2022; 30: 10–16. - PMC - PubMed
    1. Bannuru RR, Osani MC, Vaysbrot EE, et al.. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 2019; 27: 1578–1589. - PubMed

LinkOut - more resources